Program
Risperidone
Also written as “risperidone”, “Oral risperidone” and “Risperidone ISM 100 mg”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Psychotic Disorders · Autistic Disorder · Dementia, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 670 open or running | phase 4since Jun 4, 2003 | May 2, 2002 | none ahead |
| Rovi Pharmaceuticals Laboratories | 50 open or running | phase 3since May 12, 2017 | Feb 5, 2013 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 3since Apr 9, 2018 | Jan 26, 2009 | none ahead |
| AstraZeneca | 30 open or running | phase 4since Nov 14, 2005 | May 2, 2002 | none ahead |
| Luye Pharma Group | 30 open or running | phase 1since Jan 31, 2014 | Jan 31, 2014 | none ahead |
| Lyndra | 30 open or running | phase 3since Mar 9, 2023 | Sep 16, 2020 | none ahead |
| Braeburn Pharmaceuticals | 20 open or running | phase 3since May 11, 2016 | Jan 7, 2016 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Feb 4, 2010 | Feb 4, 2010 | none ahead |
| IPCA Laboratories | 20 open or running | phase 1since Jun 11, 2012 | Jun 11, 2012 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | no phasesince Oct 15, 2010 | Oct 15, 2010 | none ahead |
| Torrent Pharmaceuticals | 20 open or running | phase 1since Jul 10, 2009 | Jul 10, 2009 | none ahead |
| delpor-inc | 10 open or running | phase 2since Jun 1, 2020 | Jun 1, 2020 | none ahead |
| Indivior Pharmaceuticals | 10 open or running | phase 4since May 30, 2019 | May 30, 2019 | none ahead |
| Pfizer | 10 open or running | no phasesince Sep 9, 2005 | Sep 9, 2005 | none ahead |
| yung-shin-pharm-ind-co-ltd | 10 open or running | phase 2since Oct 23, 2023 | Oct 23, 2023 | none ahead |
Also a collaborator on its studies: Otsuka and H. Lundbeck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 10, 2005.
- Jul 14, 2017Phase 1 study in HealthyJohnson & Johnson · NCT03220867 · China
- Apr 9, 2018Phase 3 study in SchizophreniaTeva Pharmaceutical Industries · NCT03503318 · 544 enrolled · United States, Bulgaria
- May 4, 2018Phase 1 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT03527186 · 81 enrolled · United States
- Oct 18, 2018Phase 4 study in SchizophreniaJohnson & Johnson · NCT03713658 · 34 enrolled · Rwanda
- Feb 26, 2019Phase 3 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT03870880 · 215 enrolled · United States, Ukraine
- Mar 27, 2019Phase 3 study in SchizophreniaTeva Pharmaceutical Industries · NCT03893825 · 336 enrolled · United States, Bulgaria, Canada and more
- May 30, 2019Indivior Pharmaceuticals's first study: phase 4 study in SchizophreniaNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT03978832 · 69 enrolled · United States
- Jun 1, 2020delpor-inc's first study: phase 2 study in SchizophreniaNew to delpor-incdelpor-inc · NCT04418466 · 34 enrolled · United States
- Sep 16, 2020Lyndra's first study: phase 2 study in Psychotic DisordersNew to LyndraLyndra · NCT04567524 · 34 enrolled · United States
- Jun 22, 2021Phase 4 study in SchizophreniaJohnson & Johnson · NCT04940039 · 93 enrolled · Rwanda
- Dec 16, 2021Phase 1 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT05179525 · 80 enrolled · United States
- Mar 9, 2023Phase 3 study in SchizophreniaLyndra · NCT05779241 · 83 enrolled · United States
- Oct 23, 2023yung-shin-pharm-ind-co-ltd's first study: phase 2 study in Hot FlashesNew to yung-shin-pharm-ind-co-ltdyung-shin-pharm-ind-co-ltd · NCT06161792 · 10 enrolled · Taiwan
- Feb 25, 2025Phase 3 study in SchizophreniaLyndra · NCT06878833
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
Studies
The newest 60 of 99 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06878833Schizophrenia | 3 | Withdrawn | Lyndra | Dec 31, 2026 | 0 |
| NCT06161792Hot Flashes · Taiwan | 2 | Terminated | yung-shin-pharm-ind-co-ltd | Mar 14, 2022 | 10 |
| NCT05779241Schizophrenia · United States | 3 | Completed | Lyndra | Nov 3, 2023 | 83 |
| NCT05179525Schizophrenia · United States | 1 | Completed | Rovi Pharmaceuticals Laboratories | Sep 17, 2021 | 80 |
| NCT04940039Schizophrenia · Rwanda | 4 | Completed | Johnson & Johnson | Apr 16, 2024 | 93 |
| NCT04567524Psychotic Disorders · United States | 2 | Completed | Lyndra | Dec 22, 2020 | 34 |
| NCT04418466Schizophrenia · United States | 2 | Completed | delpor-inc | Feb 10, 2023 | 34 |
| NCT03978832Schizophrenia · United States | 4 | Completed | Indivior Pharmaceuticals | May 12, 2020 | 69 |
| NCT03893825Schizophrenia · United States, Bulgaria, Canada and more | 3 | Completed | Teva Pharmaceutical Industries | Dec 2, 2021 | 336 |
| NCT03870880Schizophrenia · United States, Ukraine | 3 | Completed | Rovi Pharmaceuticals Laboratories | Jan 8, 2020 | 215 |
| NCT03713658Schizophrenia · Rwanda | 4 | Completed | Johnson & Johnson | Dec 2, 2019 | 34 |
| NCT03527186Schizophrenia · United States | 1 | Completed | Rovi Pharmaceuticals Laboratories | Mar 23, 2019 | 81 |
| NCT03503318Schizophrenia · United States, Bulgaria | 3 | Completed | Teva Pharmaceutical Industries | Sep 30, 2020 | 544 |
| NCT03220867Healthy · China | 1 | Withdrawn | Johnson & Johnson | Jan 2, 2018 | 0 |
| NCT03160521Acute Schizophrenia · United States, Ukraine | 3 | Completed | Rovi Pharmaceuticals Laboratories | Dec 17, 2018 | 438 |
| NCT02773576Schizophrenia · United States | 3 | Completed | Braeburn Pharmaceuticals | Sep 2017 | 140 |
| NCT02658357Schizophrenia · United States | 2 | Completed | Braeburn Pharmaceuticals | Aug 2017 | 66 |
| NCT02634463Immunoassay · Belgium | 1 | Completed | Johnson & Johnson | Nov 9, 2016 | 81 |
| NCT02462473Schizophrenia · United States | 2 | Terminated | Johnson & Johnson | Jan 2016 | 9 |
| NCT02186769Schizophrenia · United States | 1 | Completed | Luye Pharma Group | Apr 2015 | 16 |
| NCT02091388Schizophrenia · United States | 1 | Completed | Luye Pharma Group | Jan 2015 | 108 |
| NCT02087579Psychotic Disorders · United States, Argentina, Belgium and more | 1 | Completed | Johnson & Johnson | Oct 2014 | 305 |
| NCT02055287Schizophrenia · United States | 1 | Completed | Luye Pharma Group | Jun 2014 | 36 |
| NCT01855074Schizophrenia | 4 | Completed | Johnson & Johnson | Feb 2009 | 80 |
| NCT01788774Schizophrenia · Croatia, Russian Federation, South Africa and more | 1 | Completed | Rovi Pharmaceuticals Laboratories | Feb 2014 | 36 |
| NCT01726335Schizophrenia · Brazil | 4 | Completed | Johnson & Johnson | Mar 2008 | 53 |
| NCT01722201Fasting · India | 1 | Completed | IPCA Laboratories | Sep 2012 | 48 |
| NCT01624675Autistic Disorder · Japan | 3 | Completed | Johnson & Johnson | Oct 2014 | 39 |
| NCT01618760Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | IPCA Laboratories | Jun 2012 | 48 |
| NCT01607762Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2012 | 31 |
| NCT01222975Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Oct 2004 | 44 |
| NCT01222923Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Oct 2004 | 40 |
| NCT01064271Healthy | 1 | Completed | Dr. Reddy's Laboratories | Oct 2006 | 26 |
| NCT01064232Healthy | 1 | Completed | Dr. Reddy's Laboratories | Oct 2006 | 30 |
| NCT01050582Schizophrenia · United States, Belgium, Germany and more | 4 | Completed | Johnson & Johnson | Jul 2011 | 244 |
| NCT00992407Schizophrenia · Korea, Republic of | 4 | Completed | Johnson & Johnson | Dec 2010 | 75 |
| NCT00986336Bipolar Disorder | 1 | Completed | Johnson & Johnson | 56 | |
| NCT00939926Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT00939497Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT00934635Schizophrenia · Germany | 4 | Terminated | Johnson & Johnson | Dec 2009 | 2 |
| NCT00830349Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Jul 2001 | 30 |
| NCT00829894Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Jul 2001 | 24 |
| NCT00645502Schizophrenia | 1 | Completed | Johnson & Johnson | 40 | |
| NCT00576732Autistic Disorder · United States | 4 | Completed | Johnson & Johnson | Sep 2009 | 96 |
| NCT00558298Schizophrenia | 3 | Completed | Johnson & Johnson | 811 | |
| NCT00535132Schizophrenia · United States, Argentina, Colombia and more | 4 | Completed | Johnson & Johnson | Jul 2008 | 201 |
| NCT00526877Schizophrenia · Taiwan | 4 | Completed | Johnson & Johnson | Jan 31, 2009 | 31 |
| NCT00495118Schizophrenia | 3 | Completed | Johnson & Johnson | 314 | |
| NCT00378183Psychotic Disorders | 4 | Completed | Johnson & Johnson | 120 | |
| NCT00378092Schizophrenia · South Africa | 4 | Completed | Johnson & Johnson | Mar 2010 | 33 |
| NCT00305422Schizophrenia · Germany | 3 | Completed | AstraZeneca | 45 | |
| NCT00287742Alzheimer Disease | 3 | Terminated | Johnson & Johnson | 33 | |
| NCT00266552Conduct Disorder | 3 | Completed | Johnson & Johnson | 118 | |
| NCT00261508Autistic Disorder | 3 | Completed | Johnson & Johnson | 80 | |
| NCT00257075Bipolar Disorder | 3 | Completed | Johnson & Johnson | 267 | |
| NCT00254930Learning Disabilities | 3 | Completed | Johnson & Johnson | 19 | |
| NCT00254241Schizophrenia · United Kingdom | 4 | Completed | AstraZeneca | 80 | |
| NCT00253162Bipolar Disorder | 3 | Completed | Johnson & Johnson | 439 | |
| NCT00253149Bipolar Disorder | 3 | Completed | Johnson & Johnson | 158 | |
| NCT00253136Schizophrenia | 3 | Completed | Johnson & Johnson | 458 |
How it is read
Names in the registry
- “risperidone”, 40 entries
- “Risperidone”, 34 entries
- “Oral risperidone”, 5 entries
- “Risperidone ISM 100 mg”, 3 entries
- “LY03004”, 3 entries
Codes read as this program: LYN005.
Conditions, from the studies’ own filings
- Schizophrenia, 63 studies
- Bipolar Disorder, 12 studies
- Psychotic Disorders, 3 studies
- Autistic Disorder, 3 studies
- Dementia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.